ICAM1 and inflammatory bowel disease: Future studies could investigate the effect of CCR-3 inhibition or monoclonal humanized antibody therapy to CD 11/18, ICAM-1 or VLA-4 (with Natalizumab) on eosinophil recruitment to nerves in IBD.